Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis

BMJ Open
Fiona J KinnearAidan Searle

Abstract

Individuals with heterozygous familial hypercholesterolaemia (FH) are at high risk of developing cardiovascular disease (CVD). This risk can be substantially reduced with lifelong pharmacological and lifestyle treatment; however, research suggests adherence is poor. We synthesised the qualitative research to identify enablers and barriers to treatment adherence. This study conducted a thematic synthesis of qualitative studies. MEDLINE, Embase, PsycINFO via OVID, Cochrane library and CINAHL databases and grey literature sources were searched through September 2018. We included studies conducted in individuals with FH, and their family members, which reported primary qualitative data regarding their experiences of and beliefs about their condition and its treatment. Quality assessment was undertaken using the Critical Appraisal Skills Programme for qualitative studies. A thematic synthesis was conducted to uncover descriptive and generate analytical themes. These findings were then used to identify enablers and barriers to treatment adherence for application in clinical practice. 24 papers reporting the findings of 15 population samples (264 individuals with FH and 13 of their family members) across 8 countries were included. Dat...Continue Reading

References

Mar 10, 1997·Archives of Internal Medicine·L K AndersenO Faergeman
May 16, 1998·BMJ : British Medical Journal·J Green, N Britten
Apr 16, 2002·Journal of Internal Medicine·G HollmanA G Olsson
Dec 21, 2002·American Journal of Medical Genetics. Part a·M C van MaarleG J Bonsel
Jan 14, 2003·Archives of Internal Medicine·Marina A W Umans-EckenhausenJohn J P Kastelein
Jun 5, 2004·Atherosclerosis·Fernando Civeira, UNKNOWN International Panel on Management of Familial Hypercholesterolemia
Jun 25, 2004·American Journal of Medical Genetics. Part a·Theresa MarteauUNKNOWN Genetic Risk Assessment for FH Trial Study Group
Aug 26, 2004·The Journal of Cardiovascular Nursing·Gunilla HollmanCarina Berterö
Dec 2, 2004·European Journal of Cardiovascular Nursing : Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology·Carin Alm-RoijerLeif Erhardt
Mar 17, 2005·Cardiovascular Drugs and Therapy·Victoria SeniorUNKNOWN Genetic Risk Assessment for FH Trial (GRAFT) Study Group
May 25, 2005·Patient Education and Counseling·Anders AgårdJan Wahlstöm
Oct 6, 2005·The Annals of Pharmacotherapy·Anchal SudSteven R Erickson
Nov 2, 2005·Journal of Health Services Research & Policy·Patrick ParfreyDeborah Gregory
Apr 8, 2006·The Journal of Cardiovascular Nursing·Gunilla HollmanAnna-Christina Ek
Sep 21, 2006·International Journal of Technology Assessment in Health Care·Catriona M McDaidRobert P Riemsma
May 15, 2007·Scandinavian Journal of Primary Health Care·Jan C FrichPer Fugelli
Apr 11, 2008·International Journal of Technology Assessment in Health Care·Laura HyttinenTimo E Strandberg
May 22, 2008·Community Genetics·Kate Weiner, Paul N Durrington
Jul 12, 2008·BMC Medical Research Methodology·James Thomas, Angela Harden
Nov 13, 2008·BMJ : British Medical Journal·Jorie VersmissenEric J G Sijbrands
Nov 18, 2008·American Journal of Medical Genetics. Part a·Tineke M MeulenkampEllen M A Smets
Aug 13, 2009·BMC Medical Research Methodology·Elaine Barnett-Page, James Thomas
Apr 29, 2010·Journal of Advanced Nursing·Deborah Finfgeld-Connett
Mar 1, 2002·Journal of Health Psychology·Victoria SeniorTheresa M Marteau

❮ Previous
Next ❯

Citations

Jan 3, 2020·JAMA Cardiology·UNKNOWN Representatives of the Global Familial Hypercholesterolemia CommunitySamuel S Gidding
Aug 24, 2020·Journal of Pediatric Endocrinology & Metabolism : JPEM·Engin KoseBehzat Ozkan
Aug 25, 2020·Current Opinion in Pediatrics·Uma Ramaswami, Steve E Humphries
Dec 29, 2020·PloS One·Laney K JonesAlanna Kulchak Rahm
Jun 14, 2021·The Lancet Child & Adolescent Health·M Doortje ReijmanAlbert Wiegman
Jul 31, 2021·American Journal of Preventive Cardiology·Gerald F WattsUNKNOWN FH Australasia Network Consensus Working Group
Jul 31, 2021·American Journal of Preventive Cardiology·Gisle LangsletKirsten B Holven

❮ Previous
Next ❯

Software Mentioned

NVivo
Critical Appraisal Skills Programme ( CASP )

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.